Back to Resource Center

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
July 2015
Click for full info +Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
| 17 July 2015 |
|
In this Press Release:
Health Risk(s):
HIV Product Type(s):
MicrobicidesMPTsVaccines Topic(s):
AdvocacyFunding Back to Resource Center